Shares of Sema4 Holdings Corp. (NASDAQ:SMFR – Get Rating) hit a new 52-week low during trading on Monday . The company traded as low as $1.47 and last traded at $1.48, with a volume of 7475 shares trading hands. The stock had previously closed at $1.59. A number of analysts recently commented on SMFR shares. […]
Sema4 Holdings Corp. (NASDAQ:SMFR – Get Rating) has been assigned an average recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued a report on the stock in the […]
Investment analysts at The Goldman Sachs Group began coverage on shares of Sema4 (NASDAQ:SMFR – Get Rating) in a research report issued on Thursday, The Fly reports. The firm set a “buy” rating on the stock. A number of other equities analysts have also recently issued reports on SMFR. Compass Point decreased their price objective […]
Sema4 (NASDAQ:SMFR – Get Rating) and Pear Therapeutics (NASDAQ:PEAR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Valuation & Earnings This table compares Sema4 and Pear Therapeutics’ […]
Sema4 (NASDAQ:SMFR – Get Rating) and Pear Therapeutics (NASDAQ:PEAR – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability. Profitability This table compares Sema4 and Pear Therapeutics’ net margins, […]